Clene Inc. Reports Mixed Results in 2024 Annual Report: A Look at Challenges and Opportunities in the Pharmaceutical Sector
Clene Inc., a clinical-stage pharmaceutical company known for its innovative clean-surfaced nanotechnology (CSN) therapeutics, has released its annual report for the fiscal year ending December 31, 2024. The report reveals a year marked by significant challenges, financial losses, and strategic developments aimed at propelling the company forward in its mission to address unmet medical needs in central nervous system disorders.
1. Business Overview and Strategic Developments
Founded with the mission to revolutionize therapeutic solutions, Clene Inc. focuses on the development and commercialization of CSN therapeutics, which utilize unique catalytic activities of transition element atoms to enhance cellular function. The company's flagship product, CNM-Au8, targets severe conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease (PD).
In July 2024, Clene announced a 1-for-20 reverse stock split, a move aimed at bolstering its stock price amidst ongoing operational challenges. Additionally, the company received encouraging guidance from the U.S. Food and Drug Administration (FDA) regarding CNM-Au8, suggesting a potential accelerated approval pathway for ALS treatments.
2. Financial Overview: Revenue and Losses
Revenue Breakdown
In 2024, Clene reported total revenue of $0.3 million, a sharp decline from $0.654 million in 2023. The revenue composition consisted mainly of product sales from its subsidiary, dOrbital, Inc. The breakdown is as follows:
- Royalty Income: $105,000 (down 32.69% from 2023)
- Product Sales: $237,000 (down 52.41% from 2023)
Income Statement Highlights
Clene's net loss for 2024 was $39.4 million, a slight improvement compared to the $49.5 million loss in 2023. This year's financials reflected a total operating expense of $33.43 million, composed of:
- Research and Development Expenses: $20.05 million
- General and Administrative Expenses: $13.30 million
The company’s significant non-cash expenses included stock-based compensation and changes in stock warrant liabilities, which together totaled $14.9 million.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Net Income | -49.50M | -39.4M |
Profit | -49.50M | -39.4M |
Net Income Continuing | -49.50M | -39.4M |
Pretax Income | -49.50M | -39.4M |
Non-operating Income | -9.00M | -6.30M |
Operating Income | -40.5M | -33.09M |
Revenue | 654K | 342K |
Costs and Expenses | 41.19M | 33.43M |
Cost of Revenue | 121K | 70K |
Operating Expenses | 41.07M | 33.36M |
Research & Development | 26.65M | 20.05M |
Selling, General & Administrative | 14.41M | 13.30M |
3. Balance Sheet: Asset and Liability Management
As of December 31, 2024, Clene's total assets amounted to $27.27 million, a significant decrease from $52.28 million in 2023. The assets are primarily composed of current assets of $16.15 million, which includes $12.15 million in cash and equivalents.
Conversely, the company's liabilities grew to $36.19 million, resulting in a negative equity position of $8.85 million. This highlights Clene's ongoing struggle with cash flow and operational sustainability, raising concerns about its long-term viability.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Total Assets | 52.28M | 27.27M |
Total Current Assets | 38.85M | 16.15M |
Cash and Equivalents | 28.82M | 12.15M |
Short-term Investments | 6.17M | 0 |
Net Inventories | 37K | 68K |
Accounts Receivable | 143K | 64K |
Prepaid Expenses | 3.67M | 3.87M |
Total Non-current Assets | 13.43M | 11.12M |
Net PP&E | 9.26M | 7.47M |
Lease Assets | 4.16M | 3.64M |
Total Liabilities and Equity | 52.34M | 27.33M |
Total Liabilities | 38.95M | 36.19M |
Total Current Liabilities | 25.33M | 10.29M |
Accounts Payable and Accrued Liabilities | 5.22M | 9.00M |
Current Debt | 20.10M | 1.28M |
Total Non-current Liabilities | 13.62M | 25.90M |
Long-term Debt | 1.89M | 15.42M |
Other Non-current Liabilities | 11.72M | 10.47M |
Total Equity and Non-controlling Interests | 13.39M | -8.85M |
Total Equity | 13.39M | -8.85M |
4. Cash Flow Analysis
Clene's cash flow statement for 2024 indicates a net cash used in operating activities of $21.3 million, an improvement over the previous year's $30.2 million. The company generated net cash from investing activities of $6.3 million, which included proceeds from marketable securities.
However, net cash used in financing activities amounted to $1.5 million, down from a net cash provided of $42.2 million in 2023. This decline emphasizes the company's reliance on external financing to support its operations.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Net Change in Cash | 10.48M | -16.66M |
Effect of Exchange Rate Changes | -4K | -127K |
Net Cash from Operating Activities | -30.2M | -21.3M |
Operating Profit | -49.50M | -39.4M |
Adjustment to Operating Profit | 19.30M | 18.1M |
Net Cash from Investing Activities | -1.49M | 6.31M |
Investments | 1.16M | -6.33M |
Productive Assets | 330K | 15K |
Net Cash from Financing Activities | 42.16M | -1.52M |
Debt | 269K | -10.89M |
Equity Issuance/Repurchase | 42.09M | 9.36M |
Other Financing Activities | -200K | 0 |
5. Future Outlook: Funding and Strategic Initiatives
Clene acknowledges the need for additional capital to sustain its operations and fund ongoing research and development. Future funding may be pursued through various avenues, including equity financing, debt arrangements, and potential licensing deals.
The company’s commitment to advancing its drug candidates remains strong, especially in light of the FDA's recent guidance on CNM-Au8. As Clene continues to refine its clinical trials and explore new markets, the successful execution of its strategic initiatives will be vital in overcoming current financial hurdles.
Closing Thoughts
As Clene Inc. navigates a challenging financial landscape, its focus on innovative therapeutics and strategic partnerships may provide the necessary foundation for future growth. Stakeholders will be watching closely as the company works to stabilize its financial position and advance its promising pipeline of CSN therapeutics.
